A Pilot, Randomized Study in Women of Nutrition-Related Clinical Chemistry at 6 Weeks after Roux en Y Gastric Bypass: Comparison of Two Nutrition Support Plans

  • Robert A. DiSilvestroEmail author
  • Patricia Choban
  • Fernando N. Aguila
  • Marcus Miller
  • Elizabeth Joseph
Original Contributions



The current pilot study tested a twofold hypothesis: some nutrition-related chemical measures change by 6 weeks after Roux en Y Gastric Bypass (RNYGB); one of two nutrition support plans will prevent chemical signs of nutrition problems at 6 weeks better than the other. After RNYGB, nutrition support should begin right away. However, studies on nutritional status mostly examine subjects much later. In addition, little attention has been paid to optimizing nutrition support plans.


Premenopausal females scheduled for RNYGB were given either a commercially available meal replacement product (2 servings/day) + other supplements or just a new meal replacement (2 servings/day). The latter included some nutrient versions that might enhance absorption. Blood and urine samples were taken before and 6 weeks after surgery.


In both groups, plasma vitamin D and B12 did not change, plasma osteopontin and vascular endothelial growth factor rose, while plasma retinol binding protein and a bone resorption marker declined. Copper status changes differed between groups based on plasma ceruloplasmin. Iron status improved in both groups (ferritin to c-reactive protein ratios). With the new formulation, magnesium status may have improved, urinary potassium rose, and blood sugar fell. In the other group, a liver damage marker increased, while homocysteine decreased.


Nutrition-related parameters showed varying trends 6 weeks after RNYGB. Some of the trends were affected by the type of nutritional support provided.


Bariatric Gastric bypass Nutritional status Vitamins Minerals 



The authors thank Shella Walker for help with logistics and interactions with the subjects. This research was supported partly by a loan and a small grant from Braintree Business Development Center, Mansfield, OH.

Compliance with Ethical Standards

The protocol was approved by the xxx Human Subjects Biomedical Institutional Review Board.

Conflict of Interest

All but one author declare no conflict of interest. Robert DiSilvestro is president of Medinutra LLC, a company that after the study, has been developing a commercial product that overlaps the new product tested in this study.


  1. 1.
    Isom KA, Andromalos L, Ariagno M, et al. Nutrition and metabolic support recommendations for the bariatric patient. Nutr Clin Pract. 2014;29:718–9.CrossRefGoogle Scholar
  2. 2.
    Handzlik-Orlik G, Holecki M, Orlik B, et al. Nutrition management of the post-bariatric surgery patient. Nutr Clin Pract. 2015;30:383–92.CrossRefGoogle Scholar
  3. 3.
    Peterson L. Bariatric surgery and vitamin D: key messages for surgeons and clinicians before and after bariatric surgery. Minerva Chir. 2016;71:322–36.Google Scholar
  4. 4.
    Kumar P, Hamza N, Madhok B, et al. Copper deficiency after gastric bypass for morbid obesity: a systematic review. Obes Surg. 2016;26:1335–42.CrossRefGoogle Scholar
  5. 5.
    Wardlaw GM, Hampl JS, DiSilvestro RA. Perspectives in nutrition. 6th ed. New York: McGraw Hill; 2004.Google Scholar
  6. 6.
    Calvo MS, Eyre DR, Gunberg CM. Molecular basis and clinical application of biological markers of bone turnover. Endocrinol Rev. 1996;17:333–68.Google Scholar
  7. 7.
    Scheig R. Evaluation of tests used to screen patients with liver disorders. Prim Care. 1996;23:551–60.CrossRefGoogle Scholar
  8. 8.
    Cybulsky MI, Iiyama K, Li H, et al. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Investig. 2001;107:1255–62.CrossRefGoogle Scholar
  9. 9.
    Ganguly P, Alam S. Role of homocysteine in the development of cardiovascular disease. Nutrition J. 2015;14:6.CrossRefGoogle Scholar
  10. 10.
    DiSilvestro RA, Selsby J, Siefker K. Copper supplementation effects on plasma F2α-isoprostanes and urinary collagen crosslinks in young adult women. J Trace Elem Med Biol. 2010;24:165–8.CrossRefGoogle Scholar
  11. 11.
    DiSilvestro RA, Joseph E, Raimo A, et al. Copper supplementation effects on blood copper enzymes and plasma cardiovascular health markers in middle aged people. Metabolism. 2012;61:1242–6.CrossRefGoogle Scholar
  12. 12.
    Blaner W, Li Y, Brun P, et al. Vitamin a absorption, storage and mobilization. Subcell Biochem. 2016;81:95–125.CrossRefGoogle Scholar
  13. 13.
    Carrelli A, Bucovsky M, Horst R, et al. Vitamin D storage in adipose tissue of obese and normal weight women. J Bone Miner Res. 2016;32:217–42.Google Scholar
  14. 14.
    Compston J, Vedi S, Ledger J, et al. Vitamin D status and bone histomorphometry in gross obesity. Am J Clin Nutr. 1981;34:2359–63.CrossRefGoogle Scholar
  15. 15.
    Gómez-Ambrosi J, Catalán V, Ramírez B, et al. Plasma osteopontin levels and expression in adipose tissue are increased in obesity. J Clin Endocrinol Metab. 2007;92:3719–27.CrossRefGoogle Scholar
  16. 16.
    Kahles F, Findeisen HM, Bruemmer D. Osteopontin: a novel regulator at the cross roads of inflammation, obesity and diabetes. Mol Metab. 2014;3:384–93.CrossRefGoogle Scholar
  17. 17.
    Pepys MB. The acute phase response and C-reactive protein. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine. 2nd ed. Oxford: Oxford University Press; 1995. p. 1527–33.Google Scholar
  18. 18.
    Riedl M, Vila G, Maier C, et al. Plasma osteopontin increases after bariatric surgery and correlates with markers of bone turnover but not with insulin resistance. J Clin Endocrinol Metab. 2008;93:2307–12.CrossRefGoogle Scholar
  19. 19.
    Schaller G, Aso Y, Schernthaner G, et al. Increase of osteopontin plasma concentrations after bariatric surgery independent from inflammation and insulin resistance. Obes Surg. 2009;19:351–6.CrossRefGoogle Scholar
  20. 20.
    Kiefer F, Zeyda M, Gollinger K, et al. Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance. Diabetes. 2010;59:935–46.CrossRefGoogle Scholar
  21. 21.
    Thurnham DI, Northrop-Clewes CA. Inflammation and biomarkers of micronutrient status. Curr Opin Clin Nutr Metab Care. 2016;19:458–63.CrossRefGoogle Scholar
  22. 22.
    Bovell-Benjamin A, Viteri FE, Allen LH. Iron absorption from ferrous bisglycinate and ferric trisglycinate in whole maize is regulated by iron status. Am J Clin Nutr. 2000;71:1563–9.CrossRefGoogle Scholar
  23. 23.
    Lönnerdal B. Calcium and iron absorption--mechanisms and public health relevance. Int J Vitam Nutr Res. 2010;80:293–9.CrossRefGoogle Scholar
  24. 24.
    Chan C, Low L, Lee K. Oral vitamin B12 replacement for the treatment of pernicious anemia. Front Med. 2016;3:38.CrossRefGoogle Scholar
  25. 25.
    Jahnen-Dechent W, Ketteler M. Magnesium basics. Clin Kidney J. 2012;5S:i3–i14.CrossRefGoogle Scholar
  26. 26.
    Griffith DP, Liff D, Ziegler TR, et al. Acquired copper deficiency: a potentially serious and preventable complication following gastric bypass surgery. Obesity. 2009;17:827–31.CrossRefGoogle Scholar
  27. 27.
    Gletsu-Miller N. Copper deficiency after bariatric surgery. Clin Nutr Insight. 2013;39:1–4.CrossRefGoogle Scholar
  28. 28.
    Nielsen F, Lukaski H, Johnson L, et al. Reported zinc, but not copper, intakes influence whole-body bone density, mineral content and T score responses to zinc and copper supplementation in healthy postmenopausal women. Br J Nutr. 2011;106:1872–9.CrossRefGoogle Scholar
  29. 29.
    Pratt W, Omdahl J, Sorenson J. Lack of effects of copper gluconate supplementation. A. J Clin Nutr. 1985;42:681–2.CrossRefGoogle Scholar
  30. 30.
    DiSilvestro RA, Marten JT, Skehan M. Effects of copper supplementation on ceruloplasmin and copper-zinc superoxide dismutase activities in free-living rheumatoid arthritis patients. J Am Coll Nutr. 1992;11:177–80.Google Scholar
  31. 31.
    Bosanská L, Michalský D, Lacinová Z, et al. The influence of obesity and different fat depots on adipose tissue gene expression and protein levels of cell adhesion molecules. Physiol Res. 2010;59:79–88.Google Scholar
  32. 32.
    Li S, Guerin-Deremaux L, Pochat M, et al. NUTRIOSE dietary fiber supplementation improves insulin resistance and determinants of metabolic syndrome in overweight men: a double-blind, randomized, placebo-controlled study. Appl Physiol Nutr Metab. 2010;35:773–82.CrossRefGoogle Scholar
  33. 33.
    Guerin-Deremaux L, Li S, Pochat M, et al. Effects of NUTRIOSE® dietary fiber supplementation on body weight, body composition, energy intake, and hunger in overweight men. Int J Food Sci Nutr. 2011;62:628–35.CrossRefGoogle Scholar
  34. 34.
    Aguilar-Olivos N, Almeda-Valdes P, Aguilar-Salinas C, et al. The role of bariatric surgery in the management of nonalcoholic fatty liver disease and metabolic syndrome. Metabolism. 2016;65:1196–207.CrossRefGoogle Scholar
  35. 35.
    DiSilvestro RA, Carlson GP. Effects of moderate copper deficiency on carbon tetrachloride induced hepatotoxicity in rats. Proc Soc Exp Biol Med. 1991;197:32–5.CrossRefGoogle Scholar
  36. 36.
    Martin H, Uring-Lambert B, Adrian M, et al. Effects of long-term dietary intake of magnesium on oxidative stress, apoptosis and ageing in rat liver. Magnes Res. 2008;21:124–30.Google Scholar
  37. 37.
    Sun K, Lu J, Jiang Y, et al. Low serum potassium level is associated with nonalcoholic fatty liver disease and its related metabolic disorders. Clin Endocrinol. 2014;80:348–55.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Medinutra LLCDublinUSA
  2. 2.Department of SurgeryCentral Ohio Surgical Associates, Mt Carmel Health CenterColumbusUSA

Personalised recommendations